Key clinical point: Adverse events on adjuvant sunitinib were predictable, manageable, and reversible, while decreases in health-related quality of life were not clinically meaningful except for those related to diarrhea and loss of appetite.
Major finding: The EORTC QLQ-C30 global health status/quality of life score favored placebo, with a mean difference in the overall means of –4.76 (P greater than or equal to .0001) that did not exceed the threshold that would indicate clinically meaningful deterioration.
Study details: Analysis of adverse events and patient-reported outcomes for 306 patients treated with sunitinib in the S-TRAC (Sunitinib as Adjuvant Treatment for High-Risk Renal Cell Carcinoma Following Nephrectomy) trial.
Disclosures: Pfizer sponsored the study. The authors reported disclosures related to Pfizer, Bayer, GSK, Roche, BMS, Novartis, Exelixis, AVEO, Merck, Sanofi, Astellas, Celldex, Acerta, Janssen, and others.
Staehler M et al. Ann Oncol. 2018 Aug 23. doi : 10.1093/annonc/mdy329.
This Week's Must Reads
Perioperative radiation therapy underused in elderly patients with soft tissue sarcomas, Venigalla S et al. Intl J Rad Oncology*Biology*Physics; September (102) 2018: 155-165. https://doi.org/10.1016/j.ijrobp.2018.05.019
Age, R0 resection, and adjuvant radiotherapy boost outcomes in myxofibrosarcoma, Boughzala-Bennadji R et al. Intl J Rad Oncology*Biology*Physics; October (102) 2018: 399-406. https://doi.org/10.1016/j.ijrobp.2018.05.055
Tumor size, invasion beyond subcutaneous fat predict adverse outcomes in undifferentiated pleomorphic sarcoma, Winchester D et al. J Am Acad Dermatol. Available online 19 May 2018 https://doi.org/10.1016/j.jaad.2018.05.022
High recurrence rate after pancreaticoduodenectomy for primary retroperitoneal sarcoma, Tseng W et al. European Journal of Surgical Oncology 2018 (44): June; 810-815.
Nivolumab, pembrolizumab successfully used in Kaposi sarcoma, Galanina et al. Cancer Immunol Res. 2018 Sept 7. doi: 10.1158/2326-6066.CIR-18-0121.
Must Reads in Renal Cell Carcinoma
In mRCC: Sunitinib alone not inferior to nephrectomy-sunitinib, Méjean A et al. N Engl J Med. 2018 Aug 2. doi: 10.1056/NEJMoa1803675.
Proactive management eases side effects of sunitinib treatment in RCC, Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329
Red cell distribution width might predict cancer-specific survival in RCC , Życzkowski M et al. Clinical Genitourinary Cancer 2018 June (16), e677-e683. https://doi.org/10.1016/j.clgc.2017.12.003
mRCC: Patients survive longer at high-volume centers, Joshi SS et al. Euro Urol. 2018 Sep;74:387-93.
High PD1 mRNA levels tied to anti-PD1 monotherapy response, Paré L et al. Ann Oncol. 2018 Aug 27. doi: 10.1093/annonc/mdy335.